Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

46.71 +1.82 (+4.05%)
Delayed Quote Updated: 11:57 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
6 Analysts Assess Alkermes: What You Need To Know ↗
 
Via Benzinga
News headline image
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents. ↗
ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
7 Analysts Assess Alkermes: What You Need To Know ↗
 
Via Benzinga
News headline image
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS). ↗
Should you consider ALKERMES PLC (NASDAQ:ALKS) for growth investing? 
Via Chartmill
News headline image
ALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024 ↗
ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents. ↗
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
News headline image
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS). ↗
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
Breaking Down Alkermes: 5 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Is NASDAQ:ALKS suited for growth investing? ↗
Is ALKERMES PLC (NASDAQ:ALKS) suited for growth investing? 
Via Chartmill
News headline image
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says ↗
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2... 
Via Benzinga
News headline image
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
When you look at ALKERMES PLC (NASDAQ:ALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
News headline image
NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases. ↗
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
News headline image
Exploring NASDAQ:ALKS's growth characteristics. ↗
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Alkermes's Earnings Outlook ↗
 
Via Benzinga
News headline image
Is NASDAQ:ALKS suited for growth investing? ↗
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
News headline image
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat ↗
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
News headline image
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark ↗
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
News headline image
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 ↗
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential. 
Via InvestorPlace
News headline image
Alkermes Stock Gets RS Rating Upgrade; Profits Surge ↗
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday. 
Via Investor's Business Daily
News headline image
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ ↗
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
7 Biotech Stocks Fighting America’s Deadliest Diseases ↗
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
News headline image
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength ↗
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
News headline image
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 ↗
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns 
Via InvestorPlace
News headline image
3 Top Pharma Stocks to Buy Now: February 2024 ↗
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth. 
Via InvestorPlace
News headline image
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering. ↗
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.